Results 181 to 190 of about 53,213 (267)

Shared genes and pathways in dementia: Insights from genome‐wide association studies

Alzheimer's &Dementia, Volume 21, Issue 11, November 2025.
Abstract Dementia, a collective term for neurodegenerative disorders marked by cognitive decline, affects millions worldwide, and is expected to rise significantly in prevalence. Genome‐wide association studies (GWASs), as highlighted in this review, have revolutionized our understanding of dementia by identifying contributing genetic loci and pathways,
Kyle J. Loi, Noah Radtke, Chloe Kiriluk, Mohamed H. Noureldein, Eva L. Feldman, Kelly M. Bakulski, Kevin S. Chen   +6 more
wiley   +1 more source

Genetics of Frontotemporal Dementia in the Serbian Population: Findings from a Hospital-Based Cohort. [PDF]

Neurol Int
Milošević V, Bašić J, Semnic M, Antić E, Malobabić M, Stoiljković M.   +5 more
europepmc   +1 more source

Neuropsychiatric symptom phenotypes for early detection of risk in older adults

Alzheimer's &Dementia, Volume 21, Issue 11, November 2025.
Abstract INTRODUCTION We examined whether early neuropsychiatric symptom (NPS) patterns were associated with cognitive and neuropathologic changes. METHODS Latent class analysis within 20,599 cognitively unimpaired older adults in the National Alzheimer's Coordinating Center dataset identified NPS phenotypes.
Fareshte Erani, Caitlin M. Terao, Shanna Cooper, Alexandra J. Weigand, Katherine J. Bangen, Emily C. Edmonds, David G. Coughlin, Kelsey R. Thomas   +7 more
wiley   +1 more source

Decision making in frontotemporal dementia: neuropsychological and neuroimaging assessments. [PDF]

Front Neurosci
Tavakolan Haghighi S, Bertasini C, Picari R, Paolone G.   +3 more
europepmc   +1 more source

Subtypes of multiple‐etiology dementias and the heterogeneous impact of APOE variants

Alzheimer's &Dementia, Volume 21, Issue 11, November 2025.
Abstract INTRODUCTION Multiple‐etiology dementias (MEDs) are frequently identified at autopsy but often missed in clinical diagnosis, limiting the efficiency of dementia research and treatment. This study aimed to characterize subtypes of MEDs, evaluate clinical underdiagnosis, and assess the heterogeneous impact of apolipoprotein E (APOE) variants on ...
Elizabeth Pirraglia, Ricardo S. Osorio, Lidia Glodzik, Yibeltal Ashebir, Yongzhao Shao   +4 more
wiley   +1 more source

Fourteen years later: Reviewing the diagnostic criteria for behavioral-variant frontotemporal dementia. [PDF]

Alzheimers Dement
Piguet O, Clarke AJ, Foxe D, Tse NY, Teng H, Burrell JR, Cheung SC, Carrick J, Devenney E, Halliday GM, Kwok JB, Dobson-Stone C, Cordato NJ, Hwang YT, Hodges JR, Ahmed RM.   +15 more
europepmc   +1 more source

Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations

Alzheimer's &Dementia, Volume 21, Issue 11, November 2025.
Abstract INTRODUCTION Appropriate Use Recommendations (AURs) guide real‐world use of lecanemab and donanemab in early symptomatic Alzheimer's disease (AD), but their applicability to Asian populations with diverse education backgrounds remains unclear.
So Yeon Jeon, Min Soo Byun, Hye Ji Choi, Yoon Hee Kim, Chung Hee Gwag, Yoonseok Oh, Jee Eun Park, Dahyun Yi, Gijung Jung, Hyejin Ahn, Bo Kyung Sohn, Joon Hyung Jung, Yoon Young Chang, Nayeong Kong, Hongyoon Choi, Koung Mi Kang, Chul‐Ho Sohn, Dong Young Lee   +17 more
wiley   +1 more source

Targeting Granulin Haploinsufficiency in Frontotemporal Dementia: From Genetic Mechanisms to Therapeutics. [PDF]

Int J Mol Sci
Bagyinszky E, An SSA.
europepmc   +1 more source

The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI): Overview of consortium sites and anticipated enrollment

Alzheimer's &Dementia, Volume 21, Issue 11, November 2025.
Abstract INTRODUCTION The Consortium for Clarity in Alzheimer's disease related dementias (ADRD) Research Through Imaging (CLARiTI) is a study that aims to collect standardized imaging and plasma biomarkers on 2000 Clinical Core participants enrolled across all Alzheimer's Disease Research Centers (ADRC) sites.
Julie E. Oomens, Sarah A. Biber, Marilyn Albert, Michael L. Alosco, Konstantinos Arfanakis, Tammie L. S. Benzinger, James B. Brewer, Jeffrey M. Burns, Erin Chin, Nathaniel A. Chin, Lindsay R. Clark, Ann D. Cohen, Jeffrey L. Dage, John A. Detre, Bradford C. Dickerson, Frank P. DiFilippo, Michael C. Donohue, Christopher H. van Dyck, Audrey P. Fan, Thomas J. Grabowski, Mohamad Habes, Theresa M. Harrison, Trey Hedden, Timothy J. Hohman, William J. Jagust, Angela L. Jefferson, Gregory A. Jicha, Steven R. Kecskemeti, Kejal Kantarci, Dirk C. Keene, Janice E. Knoefel, Walter A. Kukull, Weili Lin, Patrick Lao, Rebecca J. Lepping, Swati R. Levendovszky, Arjun V. Masurkar, Jonathan E. McConathy, Monica Rivera‐Mindt, Darby J. Morhardt, Douglas C. Noll, Ozioma C. Okonkwo, Todd B. Parrish, Gil D. Rabinovici, Annalise Rahman‐Filipiak, Eric M. Reiman, Shannon L. Risacher, Howie Rosen, Marc D. Rudolph, Lon S. Schneider, Lisa C. Silbert, Allen W. Song, Craig E. L. Stark, Russel H. Swerdlow, Paul M. Thompson, David Vaillancourt, Victor L. Villemagne, David A. Wolk, Deqiang Qiu, Tatiana M. Foroud, Sterling C. Johnson, Elizabeth C. Mormino   +61 more
wiley   +1 more source

Technological advances enabling an enhanced understanding of early Alzheimer's disease

Alzheimer's &Dementia, Volume 21, Issue 11, November 2025.
Abstract The aspirations of Alzheimer's disease (AD) precision medicine and precision brain health are not fully realized despite significant advances in early pathological detection. Hampering progress is the difficult challenge of the accurate detection of behavioral symptoms that can help differentiate those at high risk specific to AD versus those ...
Rhoda Au, Niranjan Bose, Farhad Imam, Vijaya B. Kolachalama   +3 more
wiley   +1 more source